Reference | Eyes | Age (mean ± SD, years) | OCTA Company | Target | Condition | Quantification |
---|---|---|---|---|---|---|
Present Study | 20 | 33.3 ± 10.1 | Optovue, Fremont, CA, USA | Conj | NE | VD |
Akagi et al., 2018 [17] | 10 | 28.5 ± 7.1 | Carl Zeiss Meditec, Dublin, CA, USA | Conj / ISV | NE | VD/VLD/VDI/FD |
Ang, et al., 2016 [18] | 8 | 45 ± 0.5 | Optovue, Fremont, CA, USA | KNV | KNV | AOV |
Allegrini, et al., 2016 [38] | 28 | / | Optovue, Fremont, CA, USA | Iris | NE | / |
Roberts, et al., 2017 [39] | 50 | 50 ± 18 | Optovue, Fremont, CA, USA | Iris | NE/ INV | / |
Ang, et al., 2018 [19] | 10 | 23–73 | AOptovue, Fremont, CA, USA, Angioscan, Nidek Co Ltd., Japan | KNV | KNV | VD |
Zett, et al., 2018 [30] | 20 | / | Optovue, Fremont, CA, USA | Iris | IP | / |
Williams, et al., 2018 [40] | 22 | 58–82 | Optovue, Fremont, CA, USA | Iris | IM | / |
Skalet, et al., 2017 [20] | 17 | 40.1 ± 10.9/ 66.4 ± 18.0 | Optovue, Fremont, CA, USA | Iris | NE/IM/BIL | VD |
Ang, et al., 2015 [21] | 30 | 49.27 ± 17.23 | Optovue, Fremont, CA, USA | KNV | KNV | AOV |
Ang, et al., 2015 [10] | 40 | 25.3 ± 7.8 | Optovue, Fremont, CA, USA | ASV | NE/CNV | VM |